Cardio Diagnostics Holdings, Inc. announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA), an official journal of the American Heart Association. This study, conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics, describes the development and validation of PrecisionCHD, a pioneering artificial intelligence-guided integrated genetic-epigenetic test for detecting coronary heart disease (CHD). The article entitled "The Validation of an Integrated Genetic-Epigenetic Test for the Assessment of Coronary Heart Disease," unveils a significant leap in CHD diagnosis.
Traditional diagnostic methods for CHD are often invasive, require exposure to ionizing radiation, and are not widely accessible due to the need for specialized infrastructure. Furthermore, some of the tests are not sensitive to all forms of CHD and can be very costly. As a result, millions of Americans do not receive adequate and potentially lifesaving cardiac care in a timely manner.
With the introduction of PrecisionCHD, clinicians now have a powerful, scalable, non-invasive alternative, in the form of a blood-based test that uses artificial intelligence (AI) and personalized genetic and epigenetic information to sensitively detect the presence of CHD. The study detailed in JAHA, conducted by researchers from Cardio Diagnostics, Intermountain Healthcare and the University of Iowa Hospitals and Clinics, describes the development and validation of the PrecisionCHD test in three independent cohorts totaling 2,516 individuals. PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD that uses the input from six methylation sensitive digital PCR (MSdPCR) assessments to determine the presence or absence of CHD.
The implications of this research are particularly relevant for rural healthcare, where access to specialized medical facilities and diagnostics is often limited. Americans in rural communities have limited access tospecialized medical facilities, fewer healthcare providers, and often, travel far greater distances for medical care . Because the PrecisionCHD test requires only a simple blood draw, patients in underserved areas will now have access to state-of-the-art cardiac assessments.